Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5988 Target Snapshot

Bcl-2-like protein 10 · SINGLE PROTEIN · Homo sapiens

7Compounds
5Assays
0Approved Drugs
6.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Bcl-2-like protein 10 shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9HD36. Start with small cell lung carcinoma, then reuse UniProt Q9HD36 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with small cell lung carcinoma, then reuse UniProt Q9HD36 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
small cell lung carcinoma

Bcl-2-like protein 10 shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with small cell lung carcinoma because it currently carries late clinical support. Linked drugs include OBATOCLAX MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bcl-2-like protein 10 as ChEMBL target CHEMBL5988, mapped to UniProt Q9HD36. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bcl-2-like protein 10
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5988
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9HD36
Bcl-2-like protein 10
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bcl-2-like protein 10 is the right protein anchor across sources, using UniProt Q9HD36 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why small cell lung carcinoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBcl-2-like protein 10
UniProt AccessionQ9HD36
Component TypeProtein
Sequence Length204 aa

Bcl-2-like protein 10

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Bcl-2-like protein 10, mapped to UniProt Q9HD36. Sequence length is 204 aa.

Mapped IDQ9HD36
Review nameBcl-2-like protein 10
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Bcl-2-like protein 10 shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase II
follicular lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase II
Hodgkins lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase II
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase II
myelofibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase I
chronic lymphocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with small cell lung carcinoma because it currently carries late clinical support. Linked drugs include OBATOCLAX MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasesmall cell lung carcinoma
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
Assay Mix

Activity Type Distribution

IC504.0
KI2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL555017 6.18 IC50 660.0 Preclinical
CHEMBL408194 6.0 Ki 1000.0 Clinical
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
2
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

5
Total Assays
2
Tested Compounds
2
Assay Types
Binding — 4 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 4 2 6.1
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine